Printer Friendly

Indigo Biosciences unveils human estrogen-related orphan receptor gamma assay system.

M2 PHARMA-September 18, 2014-Indigo Biosciences unveils human estrogen-related orphan receptor gamma assay system

(C)2014 M2 COMMUNICATIONS

18 September 2014 - US nuclear receptor screening specialist Indigo Biosciences said Thursday it had launched a human estrogen-related orphan receptor gamma (NR3B3; ERR?) assay system, including three different assay kits.

ERR? is naturally expressed in the central nervous system and at lower relative levels in multiple other tissue types, such as kidney, pancreas, skeletal muscle, heart and prostate. There has also been demonstrated cross-talk between ERR? and the estrogen receptor alpha. Moreover, functional interactions between these two nuclear receptors may influence endocrine signaling participating in the progression of breast and prostate cancers. ERR? is a potential therapeutic target for these diseases, as well as a target for anti-obesity drugs.

The nuclear receptor assay system uses proprietary mammalian reporter cells to provide high-level expression of a hybrid form of the human estrogen-related receptor gamma. In addition, the cells utilise the luciferase reporter gene, which provides a highly sensitive measure of changes in ERR? activity as a result of exposure to the user's test compounds, Indigo chief scientific officer, Dr. Jack Vanden Heuvel, noted.

The company's human ERR? assay kits are an all-inclusive, single use assay system. Besides ERR? reporter cells, the kits incorporate optimised media for use during cell culture and in diluting user test samples, a reference inverse-agonist, Luciferase Detection Reagent and a cell culture-ready assay plate. The kits are offered in 96-well, 3x32-well and 384-well assay formats.

Indigo Biosciences has a portfolio of nuclear receptor screening products and services, in addition to non-human nuclear receptor assays, functional assays and custom assay development. Its reporter cells are prepared using the firm's CryoMite process, which ensures long-term cryo-preservation of cells for shipment and storage, enabling on-demand use of the products in customers' labs.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Sep 18, 2014
Words:310
Previous Article:Thermo Fisher lists Ion PGM Dx system with FDA as class II medical device.
Next Article:SeqLL raises USD 1m for expansion of Single Molecule Sequencing.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters